Cited by 340Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Open access

Desai, Brinda S., Monahan, Angela J., Carvey, Paul M., Hendey, Bill·2007·Cell Transplantation

DOI 10.3727/000000007783464731

Open this paper in CoChat — free account

Abstract

The blood–brain barrier (BBB) is a tightly regulated barrier in the central nervous system. Though the BBB is thought to be intact during neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), recent evidence argues otherwise. Dysfunction of the BBB may be involved in disease progression, eliciting of peripheral immune response, and, most importantly, altered drug efficacy. In this review, we will give a brief overview of the BBB, its components, and their functions. We will critically evaluate the current literature in AD and PD BBB pathology resulting from insult, neuroinflammation, and neurodegeneration. Specifically, we will discuss alterations in tight junction, transport and endothelial cell surface proteins, and vascular density changes, all of which result in altered permeability. Finally, we will discuss the implications of BBB dysfunction in current and future therapeutics. Developing a better appreciation of BBB dysfunction in AD and PD may not only provide novel strategies in treatment, but will prove an interesting milestone in understanding neurodegenerative disease etiology and progression.

Integrity signals

Registry

Crossref · 10.3727/000000007783464731

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Alzheimer’s disease
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
J. Submicrosc. Cytol. Pathol.
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284
Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice
Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., & Tsukita, S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302070 · Cited by 1,917
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Astrocyte-endothelial Interactions and Blood-Brain Barrier Permeability*
Abbott, N. J. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00064.x · Cited by 1,168
Cerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102
Microglia and neuroinflammation: a pathological perspective
Streit (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-14 · Cited by 1,039
THE CELL BIOLOGY OF THE BLOOD-BRAIN BARRIER
Rubin, L. L., & Staddon, J. M. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.11 · Cited by 1,017
Complement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology
Deli, M. A., Ábrahám, C. S., Kataoka, Y., & Niwa, M. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1377-8 · Cited by 666
The large apparent work capability of the blood‐brain barrier: A study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat
Oldendorf, W. H., Cornford, M. E., & Brown, W. J. (1977) · Annals of Neurology · doi:10.1002/ana.410010502 · Cited by 651
TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587
Tight Junctions of the Blood–Brain Barrier
Kniesel, U., & Wolburg, H. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006995910836 · Cited by 535
Blood-brain barrier transport of cytokines: a mechanism for neuropathology
Banks, W. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381684 · Cited by 534
Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme
Liebner, S., Fischmann, A., Rascher, G., Duffner, F., Grote, E.-H., Kalbacher, H., & Wolburg, H. (2000) · Acta Neuropathologica · doi:10.1007/s004010000180 · Cited by 490
Immune System Response in Alzheimer's Disease
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029863 · Cited by 463
Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease
Wyss-Coray, T., Masliah, E., Mallory, M., McConlogue, L., Johnson-Wood, K., Lin, C., & Mucke, L. (1997) · Nature · doi:10.1038/39321 · Cited by 417
Neuroinflammatory processes in Parkinson's disease
Hunot, S., & Hirsch, É. C. (2003) · Annals of Neurology · doi:10.1002/ana.10481 · Cited by 407
Microglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381
The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse
Kurkowska‐Jastrzębska, I., Wrońska, A., Kohutnicka, M., Członkowski, A., & Członkowska, A. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6993 · Cited by 379
Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood–brain barrier breakdown in vivo
Bolton, S. J., Anthony, D. C., & Perry, V. H. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00058-x · Cited by 376
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 371
Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia
Tarkowski, E., Issa, R., Sjögren, M., Wallin, A., Blennow, K., Tarkowski, A., & Kumar, P. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00285-8 · Cited by 360
Deposition of Alzheimer's ??-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans
Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H. K., Siegmund, W., Kunert‐Keil, C., Walker, L. C., & Warzok, R. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00005 · Cited by 357
Cell therapy in Parkinson’s disease
Lindvall, O., & Björklund, A. (2004) · NeuroRx · doi:10.1602/neurorx.1.4.382 · Cited by 352
Brain pericytes contribute to the induction and up-regulation of blood–brain barrier functions through transforming growth factor-β production
Dohgu, S., Takata, F., Yamauchi, A., Nakagawa, S., Egawa, T., Naito, M., Tsuruo, T., Sawada, Y., Niwa, M., & Kataoka, Y. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.027 · Cited by 350
Reduced Glucose Transporter at the Blood‐Brain Barrier and in Cerebral Cortex in Alzheimer Disease
Kalaria, R. N., & Harik, S. I. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07399.x · Cited by 338
Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia
Nakayama, M., Uchimura, K., Zhu, R. L., Nagayama, T., Rose, M. E., Stetler, R. A., Isakson, P. C., Chen, J., & Graham, S. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10954 · Cited by 337
Alterations of T-lymphocyte populations in Parkinson disease
Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336
Microglia and Alzheimer's disease pathogenesis
Streit, W. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20093 · Cited by 335
Glial cell influence on the human blood‐brain barrier
Prat, A., Biernacki, K., Wosik, K., & Antel, J. P. (2001) · Glia · doi:10.1002/glia.1104 · Cited by 334
In Search of the Astrocytic Factor(s) Modulating Blood–Brain Barrier Functions in Brain Capillary Endothelial Cells In Vitro
Haseloff, R. F., Blasig, I. E., Bauer, H., & Bauer, H. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1375-x · Cited by 301
Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood–brain barrier
Wong, D. K., Dorovini‐Zis, K., & Vincent, S. R. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.008 · Cited by 264
Molecular and Cellular Characterization of the Membrane Attack Complex, C5b-9, in Alzheimer’s Disease
Webster, S. D., Lue, L., Brachova, L., Tenner, A. J., McGeer, P. L., Terai, K., Walker, D. G., Bradt, B. M., Cooper, N. R., & Rogers, J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00042-0 · Cited by 258
THE TIGHT JUNCTION: Morphology to Molecules
Stevenson, B. R., & Keon, B. H. (1998) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.14.1.89 · Cited by 256
Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys
Judith Miklossy, A., Doudet, D., Schwab, C., Yu, S. Y., McGeer, E. G., & McGeer, P. L. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.034 · Cited by 255
A population study on blood-brain barrier function in 85-year-olds
Skoog, I. G., Wallin, A., Fredman, P., Hesse, C., Aevarsson, Ó., Karlsson, I., Gottfries, C. G., & Blennow, K. (1998) · Neurology · doi:10.1212/wnl.50.4.966 · Cited by 238
Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies
van der Wal, E. A., Gómez‐Pinilla, F., & Cotman, C. W. (1993) · Neuroreport · doi:10.1097/00001756-199301000-00018 · Cited by 230
Mechanisms of the Blood–Brain Barrier Disruption in HIV-1 Infection
Toborek, M. J., Lee, Y. W., Flora, G., Pu, H., Andras, I. E., Wylęgała, E., Hennig, B., & Nath, A. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1383-x · Cited by 228
Tumor Necrosis Factor α Is Toxic to Embryonic Mesencephalic Dopamine Neurons
McGuire, S. O., Ling, Z. D., Lipton, J. W., Sortwell, C. E., Collier, T. J., & Carvey, P. M. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7688 · Cited by 222
Self-citation
Blood vessels change in the mesencephalon of patients with Parkinson's disease
Faucheux, B. A., Agid, Y., Hirsch, É. C., & Bonnet, A.-M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00641-8 · Cited by 218
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218
Self-citation
Occludin as direct target for glucocorticoid‐induced improvement of blood–brain barrier properties in a murinein vitrosystem
Förster, C. Y., Silwedel, C., Golenhofen, N., Burek, M., Kietz, S., Mankertz, J., & Drenckhahn, D. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.084038 · Cited by 212
Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients
Cláudio, L. (1995) · Acta Neuropathologica · doi:10.1007/s004010050386 · Cited by 210
Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats
Huber, J. D., VanGilder, R. L., & Houser, K. A. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00489.2006 · Cited by 206
Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure
Barcia, C., Sánchez-Bahíllo, A., Fernández‐Villalba, E., Bautista‐Hernández, V., Poza, M., Fernández-Barreiro, A., Hirsch, É. C., & Herrero, M. T. (2004) · Glia · doi:10.1002/glia.20015 · Cited by 206
Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-α and Lipopolysaccharide
Hartz, A. M. S., Bauer, B., Fricker, G., & Miller, D. S. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.017954 · Cited by 203
Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus
Baik, E. J., Kim, E. J., Lee, S., & Moon, C. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01797-7 · Cited by 200
GLUT-1 Expression in the Cerebra of Patients with Alzheimer’s Disease
Mooradian, A. D., Chung, H. C., & Shah, G. N. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00111-5 · Cited by 199
Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia
Kalaria, R. N., Cohen, D., Premkumar, D. R., Nag, S., LaManna, J. C., & Lust, W. D. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00190-9 · Cited by 190
T-Cells in Alzheimer's Disease
Town, T., Tan, J., Flavell, R. A., & Mullan, M. (2005) · NeuroMolecular Medicine · doi:10.1385/nmm:7:3:255 · Cited by 183
TNF-α knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice
Zhao, C., Ling, Z., Newman, M. B., Bhatia, A., & Carvey, P. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.012 · Cited by 183
Self-citation
The etiology of Parkinson's disease with emphasis on the MPTP story
Langston, J. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.153s · Cited by 180
Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer’s disease
Yang, S., Bae, D., Kang, H. J., Gwag, B. J., Gho, Y. S., & Chae, C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00111-8 · Cited by 178
Expression polymorphism of the blood???brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease
Furuno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178
Amyloid β-peptide1–42 alters tight junction protein distribution and expression in brain microvessel endothelial cells
Marco, S., & Skaper, S. D. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.03.047 · Cited by 176
Microvascular Dysfunction in Sepsis
Lush, C. W., & Kvietys, P. R. (2000) · Microcirculation · doi:10.1038/sj.mn.7300096 · Cited by 170
Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis
Carvey, P. M., Punati, A., & Newman, M. B. (2006) · Cell Transplantation · doi:10.3727/000000006783981990 · Cited by 164
Self-citation
Structural and Functional Variations in Capillary Systems within the Braina
Fenstermacher, J. D., Gross, P. M., Sposito, N. M., Acuff, V., Pettersen, S. E., & Gruber, K. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb51416.x · Cited by 162
Nanoparticle and other metal chelation therapeutics in Alzheimer disease
Liu, G., Garrett, M. R., Men, P., Zhu, X., Perry, G. L., & Smith, M. A. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.06.006 · Cited by 160
Clinical aspects of inflammation in Alzheimer's disease
Rosenberg, P. B. (2005) · International Review of Psychiatry · doi:10.1080/02646830500382037 · Cited by 158
Clinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157
Role of striatal l ‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats
Carta, M., Lindgren, H. S., Lundblad, M., Stancampiano, R., Fadda, F., & Cenci, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03696.x · Cited by 157
Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55
Fábry, Z., Waldschmidt, M. M., Hendrickson, D., Keiner, J., Love-Homan, L., Takei, F., & HART, M. N. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90026-h · Cited by 155
Cerebral ischemia enhances tyrosine phosphorylation of occludin in brain capillaries
Kago, T., Takagi, N., Date, I., Takenaga, Y., Takagi, K., & Takeo, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.133 · Cited by 136
Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's disease
Man, S., Ma, Y., Shang, D., Zhao, W., Li, B., Guo, D., Fang, W., Zhu, L., & Chen, Y. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.013 · Cited by 130
Astrocytes Increase the Functional Expression of P-Glycoprotein in an In Vitro Model of The Blood-Brain Barrier
Gaillard, P. J., van der Sandt, I. C. J., Voorwinden, L. H., Vu, D., Nielsen, J. L., de Boer, A. G., & Breimer, D. D. (2000) · Pharmaceutical Research · doi:10.1023/a:1026406528530 · Cited by 128
Neural Induction of the Blood–Brain Barrier: Still an Enigma
Bauer, H., & Bauer, H. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006939825857 · Cited by 127
Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients
Rota, E., Bellone, G., Rocca, P., Bergamasco, B., Emanuelli, G., & Ferrero, P. (2006) · Neurological Sciences · doi:10.1007/s10072-006-0562-6 · Cited by 125
Permeability of Proteins at the Blood–Brain Barrier in the Normal Adult Mouse and Double Transgenic Mouse Model of Alzheimer's Disease
Poduslo, J. F., Curran, G. L., Wengenack, T. M., Malester, B., & Duff, K. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0402 · Cited by 124
Effect of Oxidative Stress on the Junctional Proteins of Cultured Cerebral Endothelial Cells
Krizbai, I. A., Bauer, H., Bresgen, N., Eckl, P., Farkas, A. E., Szatmari, E. M., Traweger, A., Wejksza, K., & Bauer, H. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1378-7 · Cited by 123
Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer’s disease
Frohman, E. M., Frohman, T. C., Gupta, S., de Fougerolles, A., & van den Noort, S. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90202-i · Cited by 120
Aβ peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
Dickstein, D. L., Biron, K. E., Ujiie, M., Pfeifer, C. G., Jeffries, A. R., & Jefferies, W. A. (2006) · The FASEB Journal · doi:10.1096/fj.05-3956com · Cited by 111
Phagocytosis of ?/A4 amyloid fibrils of the neuritic neocortical plaques
Wisniewski, H. M., Barcikowska, M., & Kida, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00310142 · Cited by 109
Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease.
(1994) · PubMed Central · Cited by 105
Increased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer’s disease
Zetterberg, H., Andreasen, N., & Blennow, K. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.001 · Cited by 104
Blood-brain barrier in Alzheimer dementia and in non-demented elderly
Alafuzoff, I. I., Adolfsson, R., Grundke, I., & Winblad, B. G. (1987) · Acta Neuropathologica · doi:10.1007/bf00693782 · Cited by 104
Neurovascular Pathways and Alzheimer Amyloid β-peptide
Zlokovic, B. V., Deane, R., Sallstrom, J., Chow, N., & Miano, J. M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00103.x · Cited by 104
Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells
Maubant, S., Saint-Dizier, D., Boutillon, M., Perron‐Sierra, F., Casara, P., Hickman, J. A., Tucker, G. C., & Obberghen‐Schilling, E. V. (2006) · Blood · doi:10.1182/blood-2006-05-023580 · Cited by 98
Efflux of human and mouse amyloid β proteins 1–40 and 1–42 from brain: impairment in a mouse model of alzheimer's disease
Banks, W. A., Robinson, S. M., Verma, S., & Morley, J. E. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00474-3 · Cited by 92
Tumor necrosis factor-α−308A/G polymorphism is associated with age at onset of Alzheimer's disease
Lio, D., Annoni, G., Licastro, F., Crivello, A., Forte, G. I., Scola, L., Colonna‐Romano, G., Candore, G., Arosio, B., Galimberti, L., et al. (2006) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.01.015 · Cited by 84
Parkinson's disease and inflammatory changes
Barcia, C., Barreiro, A. F., Poza, M., & Herrero, M. T. (2003) · Neurotoxicity Research · doi:10.1007/bf03033170 · Cited by 76
Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias
Mecocci, P., Parnetti, L., Reboldi, G., Santucci, C., GAITI, A., Ferri, C., Gernini, I., Romagnoli, M., Cadini, D., & Senin, U. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb04940.x · Cited by 73
Levodopa with benserazide or carbidopa in Parkinson disease
Rinne, U. K., & Mölsä, P. K. (1979) · Neurology · doi:10.1212/wnl.29.12.1584 · Cited by 70
Vascular Endothelial Growth Factor and Blood-Brain Barrier Disruption in Tuberculous Meningitis
van der Flier, M., Hoppenreijs, S., van Rensburg, A. J., Ruyken, M., Kolk, A. H. J., Springer, P. E., Hoepelman, A. I. M., Geelen, S. P. M., Kimpen, J. L. L., & Schoeman, J. F. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000131634.57368.45 · Cited by 70
Alzheimer's disease with and without coexisting Parkinson's disease changes
Gearing, M., Schneider, J. A., Rebeck, G. W., Hyman, B. T., & Mirra, S. S. (1995) · Neurology · doi:10.1212/wnl.45.11.1985 · Cited by 66
Increased plasma levels of TNF-α but not of IL1-β in MPTP-treated monkeys one year after the MPTP administration
Barcia, C., de Pablos, V., Bautista‐Hernández, V., Sánchez-Bahíllo, A., Bernal, I., Fernández‐Villalba, E., Martín, J., Bañón, R., Fernández-Barreiro, A., & Herrero, M. T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.05.006 · Cited by 63
Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat
Jonkers, N., Sarre, S., Ebinger, G., & Michotte, Y. M. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170056 · Cited by 57
Genomewide Association, Parkinson Disease, and PARK10
Farrer, M. J., Haugarvoll, K., Ross, O. A., Stone, J. T., Milkovic, N. M., Cobb, S. A., Whittle, A. J., Lincoln, S., Hulihan, M., Heckman, M. G., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/504728 · Cited by 56
Alzheimer Disease and Its Management
Samanta, M. K., Wilson, B., Santhi, K., Kumar, K. P. S., & Suresh, B. (2006) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000208274.80496.f1 · Cited by 54
Increased T Cell Recruitment to the CNS after Amyloid β1–42Immunization in Alzheimer's Mice Overproducing Transforming Growth Factor-β1
Buckwalter, M. S., Coleman, B. S., Buttini, M., Barbour, R., Schenk, D., Games, D., Seubert, P. A., & Wyss‐Coray, T. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2436-06.2006 · Cited by 48
Effects of Benserazide on L-DOPA-Derived Extracellular Dopamine Levels and Aromatic L-Amino Acid Decarboxylase Activity in the Striatum of 6-Hydroxydopamine-Lesioned Rats
Shen, H., Kannari, K., Yamato, H., Arai, A., & Matsunaga, M. (2003) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.199.149 · Cited by 48
The potential use of a dopamine neuron antibody and a striatal‐derived neurotrophic factor as diagnostic markers in Parkinson's disease
Carvey, P. M., McRae‐Degueurce, A., Lint, T. F., Ptak, L. R., Lo, E. S., Goetz, C., & Klawans, H. L. (1991) · Neurology · doi:10.1212/wnl.41.5_suppl_2.53 · Cited by 47
Self-citation
Investigations on auto-antibodies in Alzheimer’s and Parkinson’s diseases, using defined neuronal cultures
Dahlström, A. B., Wigander, A., Lundmark, K., Gottfries, C. G., Carvey, P. M., & McRae‐Degueurce, A. (1990) · Springer eBooks · doi:10.1007/978-3-7091-9050-0_19 · Cited by 47
Self-citation
Changes in blood–brain barrier permeability following neurotoxic lesions of rat brain can be visualised with trypan blue
Reynolds, D. S., & Morton, A. J. (1998) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(97)00168-4 · Cited by 45
Differential deposition of amyloid β peptides in cerebral amyloid angiopathy associated with Alzheimer’s disease and vascular dementia
Haglund, M., Kalaria, R. N., Slade, J. Y., & Englund, E. M. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0054-z · Cited by 45
Integrity of the blood–cerebrospinal fluid barrier in early Parkinson's disease
Häussermann, P., Kuhn, W., Przuntek, H., & Müller, T. H. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01574-9 · Cited by 42
Blood vessels and Parkinsonism
Barcia, C. (2004) · Frontiers in Bioscience · doi:10.2741/1145 · Cited by 41
Does Parkinson??s Disease Have an Immunological Basis?
Fiszer, U. (2001) · BioDrugs · doi:10.2165/00063030-200115060-00001 · Cited by 31
Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood–brain barrier
Poduslo, J. F., & Curran, G. L. (2001) · Neuroreport · doi:10.1097/00001756-200110290-00011 · Cited by 31
Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?
Götz, J., Ittner, L. M., & Schönrock, N. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00615.x · Cited by 26
Neutralization of TNF by the Antibody cA2 Reveals Differential Regulation of Adhesion Molecule Expression on TNF-Activated Endothelial Cells
Nakada, M. T., Tam, S. H., Woulfe, D. S., Casper, K. A., Swerlick, R. A., & Ghrayeb, J. (1998) · Cell Communication & Adhesion · doi:10.3109/15419069809005606 · Cited by 24
In vivo Binding Behavior of Dopamine Receptor Agonist (+)−PD 128907 and Implications for the “Ceiling Effect” in Endogenous Competition Studies with [ 11 C]Raclopride—a Positron Emission Tomography Study in Macaca mulatta
Kortekaas, R., Maguire, R. P., Cremers, T. I. F. H., Dijkstra, D., van Waarde, A., & Leenders, K. L. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200405000-00007 · Cited by 22
Endothelial tight junctions form the blood–brain barrier
Bonetta, L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb1693fta1 · Cited by 19
Principles of Treatment in Parkinson's Disease
(2005) · Elsevier eBooks · doi:10.1016/b978-0-7506-5428-9.x5001-x · Cited by 18
MPP+ Injection into Rat Substantia Nigra Causes Secondary Glial Activation but Not Cell Death in the Ipsilateral Striatum
Canudas, A. M., Fríguls, B., Planas, A. M., Gabriel, C., Escubedo, E., Camarasa, J., Camins, A., & Pallàs, M. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0308 · Cited by 18
Cell replacement efforts to repair neuronal injury: A potential paradigm for the treatment of Parkinson's disease
Fillmore, H. L., Holloway, K. L., & Gillies, G. T. (2005) · Neurorehabilitation · doi:10.3233/nre-2005-20309 · Cited by 17
Glucose transport into brain: effects of hypoglycemia.
Simpson, I. A., & Vannucci, S. J. (2002) · PubMed · Cited by 10
The dam breaks: disruption of the blood-brain barrier in diabetes mellitus
Banks, W. A. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00751.2006 · Cited by 8
Chapter 78 Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor
Carvey, P. M., McRae‐Degueurce, A., Ptak, L. R., Kao, L. C., Lo, E. S., Goetz, C., Tanner, C. M., Penn, R. D., & Klawans, H. L. (1990) · Progress in brain research · doi:10.1016/s0079-6123(08)62661-8 · Cited by 6
Self-citation
Untitled work
Cann, S. A. H., Netten, J. P. V., & Netten, C. V. (2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200003)47:3

Research works printed but not linked: 14

Bernheimer H., 1973, Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 20, 415
Dahlstrom A., 1990, J. Neural Transm. Suppl., 29, 195
Desai B. S., 2006, Soc. Neurosci. Abstr.
Ehrlich P., 1904, Gesammelte Arbeiten zur Immunitaetsforschung, 574
Goldmann E., 1913, Abhandl Konigl preuss Akad Wiss, 1, 1
Iwasaki T., 1999, J. Med. Dent. Sci., 46, 31
Kalaria R. N., 1992, Cerebrovasc. Brain Metab. Rev., 4, 226
Kemper E. M., 2004, Rev., 30, 415
Larsen N., 2005, Soc. Neurosci. Abstr.
Parachikova A., 2006, Neurobiol. Aging
Sayre L. M., 2000, Cell. Mol. Biol. (Noisy-le-grand), 46, 731
Simpson I. A., 2002, Diabetes Nutr. Metab., 15, 281
Verbeek M. M., 1994, Am. J. Pathol., 144, 104
Zipser B. D., 2006, Neurobiol. Aging;

Sorted by citations

Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
Modern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,038
The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases
Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708

See all 340

Authors: Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B.
Affiliations: Department of Pharmacology, Rush University Medical Center, Chicago IL, USA
Rush University Medical Center (US)
Venue: Cell Transplantation
Publisher: SAGE Publications
Published: 2007-03
Volume: 16
Issue: 3
Pages: 285-299
ISSN: 0963-6897 (ISSN-L)
1555-3892
DOI: 10.3727/000000007783464731
OpenAlex: W2316522881
Cited by: 339
References: 117
Citations by year: 2026: 13 · 2025: 14 · 2024: 28 · 2023: 31 · 2022: 23 · 2021: 33 · 2020: 37 · 2019: 13 · 2018: 15 · 2017: 16 · 2016: 11 · 2015: 12 · 2014: 12 · 2013: 18 · 2012: 8
FWCI: 1.29
Type: journal article
Language: en
Open access: green
doaj.org
Licence: cc-by-sa
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Cell Transplantation (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Institutes of Health (5r01ns045316-03, W81XWH-04-01-0365)
U.S. Public Health Service (012307)
National Institute of Allergy and Infectious Diseases (R01AI051619, R01AI51619)
National Institute of Neurological Disorders and Stroke (NS045316)
Topics: Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: blood-brain barrier, Alzheimer's disease, Parkinson's disease, BBB dysfunction, tight junctions, blood-brain barrier permeability, neuroinflammation, neurodegeneration, brain drug delivery, vessel density, neurodegenerative disease therapeutics
MeSH terms: Alzheimer Disease, Biological Transport, Blood-Brain Barrier, Humans, Parkinson Disease, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks